Cell and Gene Therapy Today—April 9, 2026

This week’s Gene and Cell Therapy update highlights regulatory progress, clinical data validation, trial execution milestones, and continued innovation in CAR-T and gene therapy platforms.

In Today’s Newsletter

Dive deeper

🧬 Ultragenyx moves UX111 back into FDA review [1] [US • 02 Apr 2026]

https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-acceptance-bla-resubmission-ux111
Context: UX111 (rebisufligene etisparvovec, AAV9 gene therapy) targets Sanfilippo syndrome type A (MPS IIIA), a rare pediatric neurodegenerative disease.
Key point: FDA accepted the BLA resubmission for accelerated approval and set a PDUFA action date of 19 Sep 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Ray Therapeutics secures RMAT for RTx-015 [2] [US • 01 Apr 2026]

https://raytherapeutics.com/ray-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-rtx-015-in-retinitis-pigmentosa/
Context: RTx-015 is an optogenetic therapy in development for retinitis pigmentosa.
Key point: FDA granted RMAT designation based on preliminary clinical evidence indicating potential to address unmet need.
Implication: May influence prescriber choice and payer reviews pending full data.

❤️ AskBio completes Phase 2 enrollment for AB-1002 [3] [01 Apr 2026]

https://www.bayer.com/media/en-us/askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure/
Context: GenePHIT enrolled 173 adults with non-ischemic cardiomyopathy and NYHA Class III HFrEF symptoms; AB-1002 is given as a single intracoronary infusion on top of standard care.
Key point: AskBio completed randomization of the last participant in its Phase 2 study, with initial results expected in the first half of 2027.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Orca Bio review slips on CMC questions, not efficacy [4] [US • 01 Apr 2026]

https://www.fiercepharma.com/manufacturing/fda-extends-review-orca-bios-novel-cell-therapy-blood-cancers
Context: Orca-T is an engineered allogeneic cell therapy for blood cancers under FDA review.
Key point: FDA extended the target action date to 06 Jul 2026 after Orca Bio submitted additional CMC data requested by the agency.
Implication: Introduces competition that may affect pricing and formulary access.

🧠 Armatus publishes preclinical TVR110 data in CMT1A [5] [02 Apr 2026]

https://www.biospace.com/press-releases/armatus-announces-groundbreaking-data-supporting-tvr110-a-vectorized-microrna-therapy-for-the-treatment-of-charcot-marie-tooth-disease-type-1a
Context: TVR110 is an AAV9-delivered vectorized microRNA therapy designed to reduce PMP22 overexpression in Charcot-Marie-Tooth disease type 1A.
Key point: Molecular Therapy Nucleic Acids published preclinical data showing broad peripheral nerve biodistribution, controlled PMP22 silencing, and supportive safety findings.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Beam adds NEJM validation for risto-cel in sickle cell disease [6] [US • 01 Apr 2026]

https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-publication-beacon-phase-12-data
Context: Interim BEACON Phase 1/2 results covered 31 treated patients with sickle cell disease and severe VOCs, using a data cut-off of 06 Aug 2025.
Key point: NEJM published data showing rapid engraftment, durable HbF induction above 60%, HbS below 40%, and no investigator-reported severe VOCs post-engraftment.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 AvenCell doses first patient in QUADvance [7] [US • 02 Apr 2026]

https://www.prnewswire.com/news-releases/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsedrefractory-b-cell-malignancies-302732100.html
Context: AVC-203 is a CRISPR-engineered allogeneic CD19/CD20 dual-targeting CAR-T candidate for relapsed/refractory B-cell malignancies.
Key point: AvenCell announced first patient dosed in the Phase 1 QUADvance study after prior FDA IND clearance and EMA CTA approval.
Implication: May influence prescriber choice and payer reviews pending full data.

🎯 A2 Bio wins Fast Track for logic-gated A2B543 [8] [US • 01 Apr 2026]

https://www.businesswire.com/news/home/20260331789509/en/A2-Biotherapeutics-Receives-U.S.-FDA-Fast-Track-Designation-for-A2B543-a-Logic-Gated-CAR-T-Cell-Therapy-Enhanced-with-a-Membrane-Tethered-IL-12-Booster
Context: A2B543 is an autologous logic-gated CAR-T for HLA-A02 germline heterozygous adults with MSLN-positive solid tumors that have lost HLA-A02 expression.
Key point: FDA granted Fast Track designation for A2B543, which is being studied in the EVEREST-2 trial.
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 CU Anschutz clears first campus-built CAR-T for US clinical testing [9] [US • 02 Apr 2026]

https://www.prnewswire.com/news-releases/the-university-of-colorado-anschutz-gates-institute-achieves-first-in-us-fda-clearance-for-campus-built-car-t-cell-therapy-302733166.html
Context: The CD64-directed CAR-T program is moving into a Phase 1 study in adults with relapsed or refractory acute myeloid leukemia.
Key point: The University of Colorado Anschutz Gates Institute received FDA IND clearance for a CAR-T developed entirely on its campus, described as a US first for campus-built CAR-T clinical testing.
Implication: May expand screening, initiation, and follow-up at scale.

⚙️ Senti Bio publishes logic-gated CAR design framework [10] [US • 01 Apr 2026]

https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-announces-publication-cell-systems
Context: The Cell Systems paper evaluated more than 60 NOT-gated CAR circuit designs in T cells and NK cells.
Key point: Senti reported peer-reviewed data supporting design rules for dual-receptor CAR circuits intended to improve precision, efficacy, and safety while sparing healthy tissue.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🛡️ Pluristyx expands IP in stealth allogeneic cell therapy [11] [US • 07 Apr 2026]

https://www.manilatimes.net/2026/04/07/tmt-newswire/globenewswire/pluristyx-extends-patent-portfolio-in-universal-cell-therapy-with-new-us-patent-for-iact-stealth-technology/2315319
Context: The allowed claims cover iACT Stealth technology paired with self-antigen expression for autoimmune applications in iPSC-based cell therapy.
Key point: Pluristyx said it received a US patent allowance extending its universal cell therapy portfolio into tolerogenic autoimmune applications.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

FDA pathway activity was the clearest theme this week, with acceptance, designation, extension, and IND milestones across rare disease, ophthalmology, oncology, and cell therapy. [1][2][4][8][9]
Sickle cell disease and heart failure remain key late-stage proving grounds for gene and edited-cell approaches, with Beam adding publication support and AskBio completing Phase 2 enrollment. [3][6]
Logic-gated and dual-targeting CAR designs continue to gain visibility as developers try to improve selectivity in hematology and solid tumors. [7][8][10]
Academic and platform players are broadening the field beyond traditional biotech sponsors, from CU Anschutz’s campus-built CAR-T to Pluristyx’s autoimmune-oriented iPSC IP. [9][11]
Preclinical neuromuscular and retinal programs continue to build translational momentum, but human readouts remain the key next inflection point. [2][5]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cell and Gene Therapy archive on our research hub page.

FAQ

What changed for UX111 at Ultragenyx?

Ultragenyx said FDA accepted the BLA resubmission for UX111 in Sanfilippo syndrome type A and assigned a 19 Sep 2026 PDUFA date. The company also pointed to long-term follow-up and biomarker support in the filing. [1]

Why does RMAT matter for Ray Therapeutics’ RTx-015?

RMAT can increase FDA interaction and support a more efficient development path for regenerative medicine products. Ray said RTx-015 received the designation in retinitis pigmentosa based on preliminary clinical evidence. [2]

What is the practical milestone in AskBio’s AB-1002 update?

The main step is completion of enrollment in the 173-patient Phase 2 GenePHIT trial in non-ischemic HFrEF. Initial results are expected in the first half of 2027, so this is a study execution milestone, not an efficacy readout yet. [3]

Did Orca Bio’s delay reflect a clinical problem with Orca-T?

The cited report says the FDA extension was tied to chemistry, manufacturing and controls, not the clinical data. The target action date moved to 06 Jul 2026 after additional CMC information was submitted. [4]

What stands out in Beam’s risto-cel publication?

Beam highlighted 31 treated patients in BEACON, rapid engraftment, durable HbF induction above 60%, HbS below 40%, and no investigator-reported severe VOCs after engraftment. The publication also supports Beam’s planned BLA timing as early as year-end 2026. [6]

How are logic-gated CAR approaches showing up across this set?

A2 Bio received Fast Track for A2B543 in solid tumors, and Senti published a design framework for NOT-gated CAR circuits in T and NK cells. Both updates reinforce industry interest in using logic to improve tumor selectivity and reduce off-tumor effects. [8][10]

Entities / Keywords

Ultragenyx Pharmaceutical, UX111, rebisufligene etisparvovec, Sanfilippo syndrome type A, MPS IIIA, AAV9
Ray Therapeutics, RayTx, RTx-015, RMAT, retinitis pigmentosa, optogenetics
AskBio, Bayer, AB-1002, GenePHIT, heart failure with reduced ejection fraction, HFrEF, non-ischemic cardiomyopathy
Orca Bio, Orca-T, CMC, chronic GVHD-free survival, allogeneic transplant
Armatus Bio, TVR110, CMT1A, Charcot-Marie-Tooth disease type 1A, PMP22, AAV9, vectorized microRNA
Beam Therapeutics, risto-cel, BEAM-101, BEACON, sickle cell disease, SCD, VOCs, HbF, HbS
AvenCell Therapeutics, AVC-203, QUADvance, allogeneic CAR-T, CD19, CD20, CRISPR
A2 Biotherapeutics, A2 Bio, A2B543, EVEREST-2, Tmod, mem-IL-12, MSLN, HLA-A*02
University of Colorado Anschutz Gates Institute, CD64 CAR-T, AML, acute myeloid leukemia, IND clearance
Senti Biosciences, Gene Circuit platform, NOT-gated CAR, CAR NK, CAR T, Cell Systems
Pluristyx, iACT Stealth, FailSafe, iPSC, universal cell therapy, autoimmune cell therapy